Soleus Capital Management’s Tango Therapeutics TNGX Stock Holding History

Soleus Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.41M	Buy	450,000 +440,000	+4,400%	+$6.12M	0.38%	52
2025 Q4	$88.6K	Sell	10,000 -290,000	-97%	-$2.5M	﹤0.01%	95
2025 Q3	$2.52M	Sell	300,000 -430,000	-59%	-$2.91M	0.13%	69
2025 Q2	$3.74M	Buy	+730,000	New	+$1.8M	0.25%	63
2024 Q4	–	Sell	-343,152	Closed	-$2.64M	–	107
2024 Q3	$2.64M	Sell	343,152 -706,743	-67%	-$6.74M	0.2%	73
2024 Q2	$9.01M	Sell	1,049,895 -300,250	-22%	-$2.32M	0.79%	41
2024 Q1	$10.7M	Buy	1,350,145 +503,000	+59%	+$5.39M	0.8%	36
2023 Q4	$8.39M	Sell	847,145 -1,081,874	-56%	-$9.39M	0.93%	34
2023 Q3	$21.7M	Buy	1,929,019 +152,122	+9%	+$928K	2%	15
2023 Q2	$5.9M	Buy	+1,776,897	New	+$6.39M	0.66%	45

Other funds holding TNGX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Soleus Capital Management's TNGX Position: Q1 2026 in Review

Soleus Capital Management increased its Tango Therapeutics (TNGX) stake by 4,400% in Q1 2026, buying an estimated $6.12M and bringing the position to 450,000 shares worth $9.41M. The position accounts for 0.38% of the portfolio, ranked #52.

Soleus Capital Management first reported a position in TNGX in Q2 2023 and has held it in 10 quarters since. The position peaked at $21.7M in Q3 2023. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

Soleus Capital Management held 450,000 shares of Tango Therapeutics worth $9.41M as of Q1 2026.
Soleus Capital Management bought 440,000 Tango Therapeutics shares in Q1 2026, an estimated $6.12M.
Tango Therapeutics made up 0.38% of Soleus Capital Management's portfolio in Q1 2026, its #52 holding.
Soleus Capital Management first reported a position in Tango Therapeutics in Q2 2023 and has held it in 10 quarters since.
Soleus Capital Management's Tango Therapeutics position peaked at $21.7M in Q3 2023.
194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.